Europe Approves Pembrolizumab for Advanced Melanoma

[frothmouth]

“Pembrolizumab can now be marketed in all 28 European member states at the approved dose of 2 mg/kg every 3 weeks.The drug is already approved for use in the United States, but only for previously treated patients with advanced unresectable or metastatic (advanced) melanoma. Nevertheless, the Cent